Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD)
S Imashuku, T Goto, T Matsumura, M Naya… - Bone marrow …, 1997 - nature.com
S Imashuku, T Goto, T Matsumura, M Naya, M Yamori, M Hojo, S Hibi, S Todo
Bone marrow transplantation, 1997•nature.comAbstract A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic
BMT from his one locus-mismatched mother, the diagnosis being confirmed on day+ 82.
Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexa-
methasone) followed by two doses of EBV-specific CTL and one dose of unstimulated donor
leukocytes were not successful. We assume delay of infusions (day+ 100,+ 107) and
insufficient CTL cell doses (total 9.2× 10 6) may have been responsible for the poor outcome …
BMT from his one locus-mismatched mother, the diagnosis being confirmed on day+ 82.
Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexa-
methasone) followed by two doses of EBV-specific CTL and one dose of unstimulated donor
leukocytes were not successful. We assume delay of infusions (day+ 100,+ 107) and
insufficient CTL cell doses (total 9.2× 10 6) may have been responsible for the poor outcome …
Abstract
A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic BMT from his one locus-mismatched mother, the diagnosis being confirmed on day+ 82. Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexa-methasone) followed by two doses of EBV-specific CTL and one dose of unstimulated donor leukocytes were not successful. We assume delay of infusions (day+ 100,+ 107) and insufficient CTL cell doses (total 9.2× 10 6) may have been responsible for the poor outcome in this case.
nature.com